Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and…


WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers.

Read this article:
Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and...

Related Posts